My friend has mCRPC; I've posted here about
He has run through Zytiga, Xtandi, TRANSFORMER trial (BAT testosterone therapy), and is still progressing.
He's now embarked on a Phase 1 clinical trial, combining Atezolizumab with Xofigo. The Atezolizumab is for the soft tissue mets, with Xofigo for the bone mets. Here's a link to the descript
ion:Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
So far they're assessing toxicity with the combo. From the descript
ion:"This study is designed to assess the safety and tolerability of atezolizumab when given in combination with radium-223 dichloride in participants with metastatic CRPC who have progressed after treatment with an androgen pathway inhibitor. This adaptive design study includes a cohort phase and a potential randomization phase. An initial concurrent dosing evaluation will evaluate the safety and tolerability of a treatment regimen that employs a concurrent start time for atezolizumab and radium-223 dichloride (Cohort 1). "
I think he's on this initial cohort phase, so it is about
as experimental as it gets. I'm not sure he quite realizes what's involved with this kind of test. However, his PSA is running away, with many identified mets, bony and soft tissue. So, it kind of is time for a hail Mary. We owe a lot to guys who embark on these experimental trials! Here's hoping for some benefit to him.
Does anyone else here know of someone on this trial? He's doing it here at Univ of Michigan.
Bx: 6/12 pos, G9=5+4 (80%, 60%), 4+5 (2@100%, 80%, 10%), PNI+
cT3a (3T mpMRI: Bilateral EPE, NVB+, SV-, LN-)
Date PSA fPSA
9/12 4.1 15%
3/13 5.2 12% PCA3=31
IGRT by IMRT, 44 done 8/28/13: 50.4 Gy pelvic nodes, 79.2 Gy prostate
ADT2 3 yrs: Lupron/Casodex, ended 3/16
PSA <0.1 : 8/13 - 5/16;
steadying! - 0.2-8/16, 0.5-12/16, 0.7-3/17, 0.8-5/17, 0.8-7/17, 0.7-10/17